Tempus AI Inc.
Rating
Updated: Aug 18, 2026Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop an...
Latest News
11 hours ago · seekingalpha.com
Tempus AI: High Risk, But With A Great CauseTempus AI remains a Buy as I increase my position, driven by strategic moves and accelerating growth. TEM's acquisition of Personalis fills a critical MRD monitoring gap, unlocking recurring revenue and enhancing AI data assets. Q2 2026 saw 22% revenue growth, improved margins, and raised full-year guidance, despite continued operating losses.
19 hours ago · seekingalpha.com
Tempus AI: Data And Applications Will Unlock More UpsideTempus AI remains a buy after a 60% rally, driven by robust oncology testing volumes and expanding data & applications revenue. Q2 oncology testing volumes grew 31% YoY, with MRD test volumes nearly doubling since Q4 2025, validating the Personalis acquisition. Data & applications segment led Q2 growth at 28%, with strong bookings and AI innovation positioning the company for long-term growth and margin expansion.
22 hours ago · marketbeat.com
Tempus AI Sees Pricing, Data Growth Fueling Long-Term ExpansionTempus AI NASDAQ: TEM Founder and CEO Eric Lefkofsky said the company's second-quarter performance was supported by continued demand for comprehensive genomic profiling and growth in its data-licensing business.
2 days ago · defenseworld.net
Ryan Fukushima Sells 700 Shares of Tempus AI (NASDAQ:TEM) StockTempus AI, Inc. (NASDAQ: TEM - Get Free Report) CEO Ryan Fukushima sold 700 shares of the firm's stock in a transaction that occurred on Wednesday, September 16th. The shares were sold at an average price of $70.00, for a total value of $49,000.00. Following the completion of the transaction, the chief executive officer directly owned
2 days ago · defenseworld.net
Ryan Bartolucci Sells 7,062 Shares of Tempus AI (NASDAQ:TEM) StockTempus AI, Inc. (NASDAQ: TEM - Get Free Report) CAO Ryan Bartolucci sold 7,062 shares of the company's stock in a transaction dated Thursday, September 17th. The shares were sold at an average price of $75.00, for a total transaction of $529,650.00. Following the transaction, the chief accounting officer directly owned 60,804 shares of the company's
4 days ago · invezz.com
Tempus AI stock is soaring: does it have more upside to go?Tempus AI stock continues its strong bull run and is now trading at its highest level since November last year. TEM jumped to $80, up 95% from its lowest level this year, with market capitalization above $14 billion.
4 days ago · zacks.com
Strength Seen in Tempus (TEM): Can Its 14.9% Jump Turn into More Strength?Tempus (TEM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
7 days ago · seekingalpha.com
Tempus AI, Inc. (TEM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptTempus AI, Inc. (TEM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
8 days ago · youtube.com
Tempus AI CEO Eric Lefkofsky: Healthcare will likely be the biggest beneficiary of AIEric Lefkofsky, Tempus AI founder and CEO, joins 'The Exchange' to discuss AI's role in healthcare, advancing cancer research with AI, personalized vaccines, and more.
11 days ago · gurufocus.com
Tempus Launches Effort to Build the Largest Multimodal Whole-Genome Dataset to Advance AI-Driven Healthcare InnovationTempus AI, Inc. (NASDAQ: TEM) today announced an initiative to build a research platform containing 100,000 whole genomes linked to longitudinal clinical inform
Analyst Summary
Add to Watchlist
Select watchlists to add or remove TEM